University of Michigan School of Dentistry
Ann Arbor, Michigan, 48104, United States
NCT Number: NCT04462237
The present randomized clinical trial is aimed at evaluating the efficacy of recombinant human platelet-derived growth factor in combination with collagen matrix for the treatment of multiple adjacent gingival recessions
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Ann Arbor, Michigan, 48104, United States
Despite the fact that gingival recession is most often a generalized condition rather than being localized to a single tooth, most of the data currently found in the literature pertains to the treatment of localized gingival recessions.
The gold standard treatment for this condition involves the use of an autogenous connective tissue graft, that is associated with increased patient morbidity.
Biomaterials have progressively gained popularity due to their advantages when compared to autogenous grafts, such as unrestricted availability, avoidance of a secondary surgical site, reduction of the surgical time, and the patient's preference.
Collagen matrix is one of the most used soft tissue substitute for the treatment of gingival recessions. Combining this scaffold material with a growth factor could enhance its outcomes. In particular, root coverage using platelet-derived growth factor can also promote regeneration of new cementum, periodontal ligament and bone.
Therefore, the aim of the present study is to investigate the effect of platelet-derived growth factor in combination with collagen matrix outcomes for the treatment of multiple adjacent gingival recessions.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Treatment of multiple adjacent gingival recession using a coronally advanced flap
Time frame: 6 months
amount of recession reduction compared to the baseline recession depth
Time frame: 6 months
amount of keratinized tissue width gain from the baseline
Time frame: 6 months
amount of gingival thickness gain from the baseline
Time frame: 6 months
Soft tissue volumetric variation evaluated with digital softwares
Time frame: 6 months
Tissue perfusion variations compared to baseline at the different follow-up using ultrasonography
Time frame: 6 months
Patient self reported perception of the procedure in terms of morbidity, satisfaction and esthetic outcomes. Visual analogue scales (from 0 to 100) will be used to assess these outcomes
Time frame: 6 months
evaluated using the root coverage esthetic score (from 0 to 10)
Time frame: 3 months
Within-subject difference between the concentrations at the control and test sites
University of Michigan
Other
The Effect of Recombinant Human Platelet-derived Growth Factor in Combination With Collagen Matrix for the Treatment of Multiple Adjacent Gingival Recessions: A Randomized Clinical Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07736833
Gingival Diseases, Gingival Recession
Tanta, Gharbia Governorate, Egypt
View Trial DetailsNCT05470660
Gingival Diseases, Gingival Recession
Cairo, Egypt
View Trial DetailsNCT07291583
Gingival Diseases, Gingival Recession
Ankara, None Selected, Turkey (Türkiye)
View Trial DetailsNCT07616960
Gingival Diseases, Gingival Recession
Taipei, Taiwan
View Trial Details